Raphas Co., Ltd.

Company Introduction

The corporate name, RAPHAS is a combination of two words: Rapha, which means ‘heal’ and Path, which means ‘passage’. This represents our objective to become a path towards healing for all of humankind.
The foundation of RAPHAS is closely connected with the aspirations of professional researchers of biotechnology.
The efforts of the researchers who have dreamed of developing the practical technology based on each of their knowledge and their research paid off.
The remarkable way for enjoying ‘the healthier life, without pain’ is the future of drug delivery system which has been put forward by RAPHAS.
The ‘Dissolving Microneedle Patch’ is the new paradigm of drug delivery platform which has solved the problems of those existing drug delivery system.
The Microneedle made with the unique manufacturing method DEN (Droplet Extension) materializes the system for allowing penetration through the skin barrier and enables anyone to painlessly and conveniently apply the patch on their own.
RAPHAS will open the road to treatment for everyone in the world.

RAPHAS own patented technology can be developed into various products in any field needing delivery of active ingredients through the skin.
Currently, in the cosmetics market the patches with various ingredients are produced and distributed through the Original Design Manufacturer(ODM) system, and they are expected to enter into the medical market by utilizing the Contract Development and Manufacturing Organization(CDMO) system.
The safe and effective technology, as well as the economic feasibility has become popular not only in Asia but also in many countries around the world.
RAPHAS’ cosmetic patches have been successfully entered into the markets of South Korea, Japan, the US, the EU, China, and even Australia.

RAPHAS’ Microneedle technology, which has drawn worldwide attention, is evolving even now. The future of RAPHAS which started from cosmetics patches is now making the leap toward medicine for topical skin diseases, medical products for disease treatment, and even toward vaccination patches.
GOLDGOLD
  • Response Level
      less than 30%
  • Supplier Level
      More than 10 billion (KRW)
  • Transaction Level
      less than 5